Literature DB >> 3674773

Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.

H Olsson1, B Lindahl, J Ranstam, A Borg, M Fernö, A Norgren.   

Abstract

In 65 young women undergoing curettage for benign uterine disorders a significant relationship was found between early oral contraceptive use (starting age less than 25 years) and a high ratio of ln plasma prolactin versus ln estrogen receptor concentration of the uterine mucosae (p less than 0.047, Mann-Whitneys U-test). Year of birth, age at menarche, age at first full term pregnancy, parity, menstrual cycle phase and duration of oral contraceptive use could not explain the results. Because similar results have previously been found for breast cancer patients using plasma prolactin and breast tumour estrogen receptor concentration, the findings indicate that early oral contraceptive use permanently alters plasma prolactin levels and estrogen receptor concentration, both in benign uterine tissue and in malignant breast tumours.

Entities:  

Keywords:  Age Factors; Biology; Bleeding; Breast Cancer; Cancer; Contraception; Contraceptive Methods--side effects; Curettage; Demographic Factors; Developed Countries; Diseases; Endocrine System; Estrogens; Europe; Family Planning; Genitalia; Genitalia, Female; Hormone Receptors; Hormones; Membrane Proteins; Metrorrhagia; Neoplasms; Northern Europe; Obstetrical Surgery; Oral Contraceptives--side effects; Physiology; Pituitary Hormones; Population; Population Characteristics; Prolactin; Scandinavia; Signs And Symptoms; Surgery; Sweden; Treatment; Urogenital System; Uterine Effects; Uterus

Mesh:

Substances:

Year:  1987        PMID: 3674773

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Breast cancer and the pill.

Authors:  H Olsson; J Ranstam
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.